Eden Research PLC, an AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technologies, announced that Derek McAllan, a Non-Executive Director, has purchased 323,017 ordinary shares at a price of 4.6437 pence per share. Following the purchase, McAllan's interest in the company's share capital is 0.06%. Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture, developing and supplying innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health, and consumer products industries.
The company's products are formulated with terpene active ingredients, based on natural plant defense metabolites, and have been primarily used on high-value fruits and vegetables, improving crop yields and marketability. Eden has three products currently on the market: Mevalone®, a foliar biofungicide; Cedroz™, a bionematicide; and Ecovelex™, a seed treatment product developed to tackle crop destruction caused by birds. Additionally, Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants and can be used with both natural and synthetic compounds to enhance their performance and ease-of-use.
Eden Research was admitted to trading on AIM in 2012 and was awarded the London Stock Exchange Green Economy Mark in 2021. The company derives 100% of its total annual revenues from sustainable products and services. For further information, please visit the company's website at www.edenresearch.com.